Evidence map›Paper›PMID 21658230›Full record

ArticleBMC biotechnology2011

Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein.

Tiina A Riihimäki, Soili Hiltunen, Martina Rangl, Henri R Nordlund, Juha A E Määttä, Andreas Ebner, Peter Hinterdorfer, Markku S Kulomaa, Kristiina Takkinen, Vesa P Hytönen

Abstract read
In one paragraph

Article in BMC biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tiina A RiihimäkiInstitute of Biomedical Technology, University of Tampere and Tampere University Hospital, FI-33520 Tampere, Finland.
Soili Hiltunen
Martina Rangl
Henri R Nordlund
Juha A E Määttä
Andreas Ebner
Peter Hinterdorfer
Markku S Kulomaa
Kristiina Takkinen
Vesa P Hytönen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEngineered proteins, with non-immunoglobulin scaffolds, have become an important alternative to antibodies in many biotechnical and therapeutic applications. When compared to antibodies, tailored proteins may provide advantageous properties such as a smaller size or a more stable structure.

resultsAvidin is a widely used protein in biomedicine and biotechnology. To tailor the binding properties of avidin, we have designed a sequence-randomized avidin library with mutagenesis focused at the loop area of the binding site. Selection from the generated library led to the isolation of a steroid-binding avidin mutant (sbAvd-1) showing micromolar affinity towards testosterone (Kd ~ 9 μM). Furthermore, a gene library based on the sbAvd-1 gene was created by randomizing the loop area between β-strands 3 and 4. Phage display selection from this library led to the isolation of a steroid-binding protein with significantly decreased biotin binding affinity compared to sbAvd-1. Importantly, differential scanning calorimetry and analytical gel-filtration revealed that the high stability and the tetrameric structure were preserved in these engineered avidins.

conclusionsThe high stability and structural properties of avidin make it an attractive molecule for the engineering of novel receptors. This methodology may allow the use of avidin as a universal scaffold in the development of novel receptors for small molecules.

Indexed as

AvidinBinding SitesCalorimetry, Differential ScanningGene LibraryKineticsLigandsPeptide LibraryProtein BindingProtein EngineeringProtein Structure, QuaternaryTestosteroneAvidinLigandsPeptide LibraryTestosterone

Identifiers

PMID21658230
PMCPMC3201017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.